As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

How long it takes to lose weight can vary based on a number of factors, such as age, medications you take, your activity ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

Fridays offers a subscription-based weight loss service. Its program includes virtual consultations with a health care provider, compounded GLP-1 medications, lifestyle and nutrition coaching, and ...

With an FDA-approved treatment like Wegovy, healthcare professionals and patients can have confidence in safety, effectiveness and quality, knowing it has undergone rigorous regulatory review.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

"After a review of the totality of information ... which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...